Get the Stockscreener App
2.60
1.96%
0.05
After Hours:
2.59
-0.01
-0.38%
Savara Inc stock is traded at $2.60, with a volume of 768.59K.
It is up +1.96% in the last 24 hours and down -5.45% over the past month.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
See More
Previous Close:
$2.55
Open:
$2.54
24h Volume:
768.59K
Relative Volume:
0.80
Market Cap:
$446.21M
Revenue:
-
Net Income/Loss:
$-54.70M
P/E Ratio:
-7.8788
EPS:
-0.33
Net Cash Flow:
$-51.36M
1W Performance:
+0.00%
1M Performance:
-5.45%
6M Performance:
-38.68%
1Y Performance:
-47.15%
1-Day Range:
$2.50
$2.63
1-Week Range:
$2.425
$2.7215
52-Week Range:
$2.31
$5.34
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.60 | 446.21M | 0 | -54.70M | -51.36M | -0.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Savara Inc. to Present at Leerink Global Healthcare Conference - MSN
Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA): An Enticing Stock To Watch - Stocks Register
Savara, Inc. to Host Earnings Call - ACCESS Newswire
Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell -March 06, 2025 at 08:55 am EST - Marketscreener.com
Game-Changing Finger-Prick Test Could Transform Rare Lung Disease DiagnosisWhat Makes It Special? - StockTitan
Savara Announces Participation in the Leerink Global Healthcare Conference - Joplin Globe
Rare Disease Biotech Savara Sets Key Investor Presentation at Leerink Conference - StockTitan
Savara (SVRA) Expected to Announce Earnings on Thursday - Defense World
Savara Insiders Lose Out As Stock Sinks To US$2.56 - Simply Wall St
SVRA stock touches 52-week low at $2.58 amid market challenges - Investing.com Australia
SVRA stock touches 52-week low at $2.58 amid market challenges By Investing.com - Investing.com South Africa
Analysts Set Savara Inc (NASDAQ:SVRA) Price Target at $9.86 - Defense World
Savara Inc. Awards Stock Options and RSUs to New Employees - MSN
SVRASavara Inc Latest Stock News & Market Updates - StockTitan
Savara Announces New Employment Inducement Grant - Milton Daily Standard
Savara's Latest Executive Compensation Package Revealed: Key Details on New Employee Stock Awards - StockTitan
A company insider recently sold 25,000 shares of Savara Inc [SVRA]. Should You Sale? - Knox Daily
SG Americas Securities LLC Has $158,000 Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
SVRA’s latest rating updates from top analysts. - Knox Daily
Positive Signs As Multiple Insiders Buy Savara Stock - Yahoo Finance UK
Investing in Savara Inc (SVRA) Is Getting More Attractive - Knox Daily
Savara Inc. to Present at Upcoming Healthcare Investor Conferences - MSN
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment - MSN
Analysts Predict How High Savara Inc (SVRA) Will Go. - Stocks Register
JPMorgan Chase & Co. Purchases 13,420 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Molgramostim shows promise in rare lung disease treatment - MSN
SVRA stock touches 52-week low at $2.6 amid market challenges - MSN
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research - Business Wire
Savara Announces Participation in Upcoming Healthcare Investor Conferences - The Bakersfield Californian
Rare Disease Pioneer Savara Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Savara Inc (NASDAQ:SVRA) Receives $9.86 Average PT from Brokerages - Defense World
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Title: Savara Inc. Approves 2025 Executive Officers’ Target Bonus Amounts - Defense World
Savara sets executive bonus targets for 2025 - MSN
Savara sets executive bonus targets for 2025 By Investing.com - Investing.com Australia
Savara Sets 2025 Executive Bonus Targets - TipRanks
Savara Inc Updates Corporate Presentation in Latest SEC Filing - Defense World
Savara (NASDAQ:SVRA) Stock Price Down 5.3%Here's What Happened - MarketBeat
Savara Inc. Launches Early Access Program for Rare Lung Disease Treatment - MSN
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):